Table 3.
Comparison of baseline characteristics between treated and untreated subjects in the original sample and in the propensity score-matched sample
| Baseline variables | Original sample | Matched sample | ||||
|---|---|---|---|---|---|---|
| Treated group (n = 604) | Control group (n = 1242) | Mean difference | Treated group (n = 604) | Control group (n = 1242) | Mean difference | |
| Global distance | 0.3726 | 0.2981 | 0.0745 | 0.3726 | 0.3723 | 0.0002 |
| Demographics data | ||||||
| Age | 52.1780 | 51.0113 | 1.1667 | 52.1780 | 51.8061 | 0.3719 |
| Female | 0.4068 | 0.4042 | 0.0026 | 0.4068 | 0.4156 | − 0.0088 |
| Male | 0.5932 | 0.5958 | − 0.0026 | 0.5932 | 0.5844 | 0.0088 |
| Severity of illness | ||||||
| APACHE II score | 16.0763 | 15.1216 | 0.9547 | 16.0763 | 15.6660 | 0.4102 |
| SOFA score | 5.8797 | 5.8277 | 0.0520 | 5.8797 | 5.6419 | 0.2378 |
| Health care and disease | ||||||
| Delay at hospital admission | 4.8610 | 4.7206 | 0.14 | 4.8610 | 4.6045 | 0.2565 |
| Delay at ICU admission | 2.6864 | 2.1578 | 0.5286 | 2.6864 | 2.5346 | 0.1519 |
| Primary viral pneumonia | 0.7746 | 0.8003 | − 0.0257 | 0.7746 | 0.8010 | − 0.0264 |
| Bacterial co-infection | 0.2254 | 0.1997 | 0.0257 | 0.2254 | 0.1990 | 0.0264 |
| Number of quadrants infiltrated in chest X-ray | 2.4864 | 2.4308 | 0.0557 | 2.4864 | 2.4880 | − 0.0016 |
| Laboratory | ||||||
| Serum LDH levels | 832.2373 | 832.3132 | − 0.0759 | 832.2373 | 837.3178 | − 5.0805 |
| Serum CPK levels | 1633.3464 | 1564.6452 | 68.7013 | 1633.3464 | 1608.0373 | 25.3092 |
| WBC count | 10,058.1576 | 9255.0539 | 803.1037 | 10,058.1576 | 10,008.3259 | 49.8318 |
| Serum PCT levels | 6.0390 | 6.8203 | − 0.7813 | 6.0390 | 5.3273 | 0.7117 |
| Serum CRP levels | 65.1844 | 75.8709 | − 10.6865 | 65.1844 | 65.3580 | − 0.1736 |
| Serum urea levels | 52.0131 | 51.5584 | 0.4547 | 52.0131 | 49.5200 | 2.4931 |
| Comorbidities | ||||||
| Asthma | 0.1305 | 0.0604 | 0.0701 | 0.1305 | 0.1339 | − 0.0034 |
| COPD | 0.2593 | 0.1441 | 0.1152 | 0.2593 | 0.2568 | 0.0025 |
| Chronic heart disease | 0.0898 | 0.1023 | − 0.0124 | 0.0898 | 0.0895 | 0.0003 |
| Chronic renal disease | 0.0864 | 0.0805 | 0.0059 | 0.0864 | 0.0920 | − 0.0056 |
| Hematological disease | 0.1085 | 0.0556 | 0.0529 | 0.1085 | 0.0939 | 0.0146 |
| Pregnancy | 0.0356 | 0.0419 | − 0.0063 | 0.0356 | 0.0400 | − 0.0406 |
| Diabetes mellitus | 0.1712 | 0.1683 | 0.0029 | 0.1712 | 0.1733 | − 0.0021 |
| Obesity | 0.3695 | 0.3140 | 0.0555 | 0.3695 | 0.4101 | − 0.0406 |
| HIV-AIDS | 0.0390 | 0.0193 | 0.0197 | 0.0390 | 0.0224 | 0.0166 |
| Neuromuscular disease | 0.0203 | 0.0290 | − 0.0086 | 0.0203 | 0.0274 | − 0.0071 |
| Autoimmune disease | 0.0508 | 0.0298 | 0.0211 | 0.0508 | 0.0497 | 0.0011 |
| Complications | ||||||
| Acute kidney failure | 0.2102 | 0.2303 | − 0.0201 | 0.2102 | 0.1977 | 0.0124 |
| CRRT | 0.0983 | 0.0910 | 0.0073 | 0.0983 | 0.0953 | 0.0030 |
| Mechanical ventilation | 0.8390 | 0.7432 | 0.0958 | 0.8390 | 0.8587 | − 0.0197 |
| Shock | 0.5153 | 0.5072 | 0.0080 | 0.5153 | 0.4875 | 0.0278 |
APACHE II Acute Physiology and Chronic Health Evaluation II score, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, LDH lactate dehydrogenase, CPK creatine phosphokinase, WBC white blood cells, PCT procalcitonin, RCP C-reactive protein, COPD chronic obstructive pulmonary disease, HIV/AIDS human immunodeficiency virus/acquired immunodeficiency syndrome, CRRT continuous renal replacement therapy